Vomiting gets attention in a way nausea never quite does, and it is also one of the best documented side effects in the class: every GLP-1 prescribing information reports it in the adverse reaction tables with the placebo column printed right beside it. Gathering those figures in one place is the first job here. The second is the question that follows a bad night: did the dose count? The third is knowing where ordinary vomiting ends and the label's named warning begins, because the labels treat those as two different subjects.
Two neighbouring pages already carry their parts of this ground. A stomach illness that arrives on top of a GLP-1, the levels of care, and the dose question while genuinely sick belong to Sick Days on a GLP-1: Vomiting, Dehydration and When to Call. Nausea itself, with the comfort measures commonly suggested for it, belongs to Nausea on GLP-1s: The Patterns Worth Tracking. What remains, and what belongs here, is vomiting caused by the medicine itself.
How often the trials recorded it
The figures below come from the adverse reaction sections of the current US labels. They are trial results: descriptions of what happened to the people enrolled, at the doses studied, and nothing in them is a forecast for any reader.
| Product and trial population | On the medicine | On placebo |
|---|---|---|
| Wegovy 2.4 mg, adults, weight reduction | 24% | 6% |
| Wegovy 7.2 mg trial, adults at 7.2 mg | 22% | 6% |
| Wegovy 68-week trial, 201 patients aged 12 and older | 36% | 10% |
| Ozempic 0.5 mg | 5% | 2.3% |
| Ozempic 1 mg | 9.2% | 2.3% |
| Rybelsus and Ozempic tablets, across doses | 6% and 8% | 3% |
| Zepbound 5, 10 and 15 mg | 8%, 11% and 13% | 2% |
| Mounjaro 5, 10 and 15 mg | 5%, 5% and 9% | 2% |
| Saxenda, adult pool | 15.7% | 3.9% |
| Victoza, across doses | 6% and 9% | 2% |
| Trulicity 0.75 mg and 1.5 mg | 6.0% and 12.7% | 2.3% |
| Byetta twice daily, as monotherapy | 4% | 0% |
| Byetta added to a sulfonylurea | 13% | 4% |
| Byetta added to insulin glargine | 18% | 4% |
The 36 percent figure needs its population named: it comes from a 68-week Wegovy trial of 201 patients aged 12 and older, and describes that group rather than adults in the weight-management trials. In the 7.2 mg trial, adults on the 2.4 mg strength recorded 16 percent against 6 percent on placebo.
The placebo column is printed in every one of those tables, and it is never zero except in Byetta's monotherapy trial. That is worth a sentence of its own, because a placebo column that is usually small but rarely absent is what makes the medicine column readable at all. A rate of 9 percent against 2 percent and a rate of 9 percent against 8 percent would be entirely different findings, and the tables exist precisely so that nobody has to guess which one they are reading.
Two patterns the numbers support
The first pattern is that vomiting rises with dose within a product. Zepbound records 8 percent at 5 mg, 11 percent at 10 mg and 13 percent at 15 mg, and Trulicity records 6.0 percent at 0.75 mg against 12.7 percent at 1.5 mg. That is a fact about the trials as run. It is not a statement about what any reader's next step should be, and what to make of it, if anything, is a prescriber conversation in every case.
The second pattern appears in the two molecules sold under both a diabetes brand and a weight-management brand: the same molecule records more vomiting at weight-management doses than at diabetes doses. Tirzepatide reached 13 percent at Zepbound's 15 mg strength against 9 percent at Mounjaro's 15 mg, and liraglutide recorded 15.7 percent in Saxenda's adult pool against 9 percent on Victoza. Different trials, different populations and different dose ladders stand behind those pairs. But the direction repeats across both molecules, which is why it reads as a pattern rather than a one-off.
The severe end is a different section
Common vomiting sits in the adverse reaction tables. The severe end of the gastrointestinal story sits in Warnings and Precautions, under a heading every label in the class carries: Severe Gastrointestinal Adverse Reactions. The Wegovy label puts numbers on that warning too. Severe gastrointestinal adverse reactions were reported in 4.1 percent of Wegovy injection patients against 0.9 percent on placebo, and in 2 percent of Wegovy tablet patients against none on placebo. The same section states that Wegovy is not recommended in patients with severe gastroparesis, and the label's revision history dates that warning to October 2025.
The two kinds of number are not two versions of one claim. The 24 percent figure in the trial table describes ordinary vomiting among adults taking the medicine; the 4.1 percent figure describes reactions severe enough to belong in the warning section. Neither can be read as the other. Severe abdominal pain, the symptom that gets its own urgent framing, is carried in full at Severe Abdominal Pain on a GLP-1 Is Never a “Wait and See”.
Why vomiting earns a warning at all
The route that turns a stomach problem into a serious one runs through fluid volume. Every label in the class ties dehydration to the gastrointestinal reactions, naming nausea, vomiting and diarrhea together, and warns that dehydration has led to acute kidney injury. The labels instruct clinicians to monitor renal function in patients reporting reactions that could lead to volume depletion, which is the class's way of saying the danger is the drain, not the symptom itself. That chain is laid out in full at GLP-1s and Your Kidneys: Why Dehydration Is the Risk, and the daily habits that keep fluid intake steady are covered in Why Hydration Matters More on a GLP-1.
Did the dose count?
For the injections, the answer is plain, and it is the single most useful sentence on this page: an injection does not come back up. The medicine was deposited under the skin, and vomiting afterwards does not remove it. The dose is in, and it stays in, whether the moment came soon after the injection or the next morning.
For the tablets, the question is real and the labels do not answer it. The shared Rybelsus and Ozempic tablets label and the Wegovy tablets label contain no instruction about vomiting shortly after a dose and no instruction about taking another tablet. That is silence, not a hidden instruction pointing either way, and the right interpreter of a silent label is the prescriber or the pharmacist who dispensed it. A genuinely missed dose is a different situation entirely, one the labels do address explicitly, and Missed Your GLP-1 Dose? What the Official Guidance Says carries that guidance product by product.
What to log
Vomiting that clusters after shot day, or gathers around a dose increase, is a pattern a prescriber can work with, and memory is famously bad at patterns. In GLP 1 Tracker, the side effect diary takes a dated entry with a severity rating, and dose entries carry their own dates, so a run of entries in the two days after an injection sits next to the injection itself instead of being reconstructed weeks later. The week after a step up the ladder has its own page at The Week After a Dose Increase, and the wider discipline of showing the record rather than the recollection is laid out in How to Track GLP-1 Side Effects (and What to Show Your Doctor).
Persistent vomiting, signs of dehydration, or severe abdominal pain are not logging questions. They belong with a clinician, promptly, and everything above is the background to that conversation rather than a substitute for it.
Frequently asked questions
If I throw up after my weekly GLP-1 shot, did the dose still count?
For the injections, yes. The medicine was deposited under the skin, and vomiting afterwards does not remove it; a weekly or daily injection does not come back up. For the tablets the labels are silent: neither the shared Rybelsus and Ozempic tablets label nor the Wegovy tablets label says anything about vomiting shortly after a dose or about taking another tablet. That question belongs with the prescriber or the pharmacist.
How often did vomiting happen in the GLP-1 trials?
It ranged widely by product and dose, always with the placebo column printed beside it. Wegovy 2.4 mg recorded vomiting in 24 percent of adults against 6 percent on placebo, while Ozempic recorded 5 percent at 0.5 mg and 9.2 percent at 1 mg against 2.3 percent on placebo. Within a product the rate rises with dose: Zepbound recorded 8, 11 and 13 percent at its 5, 10 and 15 mg strengths. These are trial results, not predictions for any reader.
Is vomiting the same as the severe gastrointestinal warning on the label?
No, and the two live in different sections. Common vomiting sits in the adverse reaction tables. The warning, headed Severe Gastrointestinal Adverse Reactions, covers the severe end: the Wegovy label reports severe gastrointestinal adverse reactions in 4.1 percent of injection patients against 0.9 percent on placebo, states that Wegovy is not recommended in patients with severe gastroparesis, and dates that warning to October 2025 in its revision history.
When does vomiting on a GLP-1 need medical attention?
Persistent vomiting, signs of dehydration, or severe abdominal pain belong with a clinician rather than with waiting. The labels tie gastrointestinal reactions to dehydration and warn that dehydration has led to acute kidney injury, which is why they instruct clinicians to monitor renal function in patients reporting reactions that could lead to volume depletion.
How should I record vomiting so my prescriber can see the pattern?
In GLP 1 Tracker the side effect diary takes a dated entry with a severity rating, and every dose entry carries its own date, so vomiting clustered in the days after a shot or around a dose increase is visible on the record instead of reconstructed from memory. A free-text note can be attached to either entry, and Premium adds 90-day side effect trend charts for the longer view.